Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Clot lysis" patented technology

Clot lysis. the time required for a clot to lyse at 98.6°F (37°C) is a reflection of the plasmin content of the blood. Clot retraction and fibrinogen content of the blood sample are also influential.

Anticoagulant compounds comprising chelating agents and cationic Anti-coagulation enhancers and methods and devices for their use

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including at least one of a chelating agent, a direct factor Xa inhibitor, a direct factor IIa inhibitor, and a factor XI / XIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent a target site in the patient's body. The therapeutic composition is formulated to release the one or more active substances to the target site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and / or inhibit cell proliferation. Delayed or other controlled release of the therapeutic composition from the structure may be provided.
Owner:ELIXIR MEDICAL CORP

Anti-A2AP antibodies and uses thereof

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.
Owner:BAYER AG

Anti-A2AP antibodies and uses thereof

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.
Owner:BAYER AG

Apparatus and method for clot brake pressure measurement

Devices and methods for clot bursting pressure measurement are disclosed herein. Particular embodiments include a pump, a pressure measurement device, and a container having an inlet, an outlet, and an orifice. In particular embodiments, a pump is coupled to an inlet of a container, a pressure measurement device is coupled to an outlet of the container, and an orifice is configured to hold fluid extending across the orifice.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

In vitro measurement of fibrin clot lysis

The invention relates to an in vitro method for measuring fibrin clot degradation based on a fibrin clot lysis curve over time in a blood or plasma sample previously obtained from a patient suspected of having a deficiency in at least one coagulation factor. This method includes determining a baseline fibrin clot level at time t1 and determining a degraded fibrin clot level at a subsequent time t2. The method may include an additional step of classifying the tested sample into a group reflecting a fibrin clot lysis profile. The invention also relates to a method for monitoring therapeutic treatment administered to a patient suspected of having, or who has, a deficiency in at least one coagulation factor. This method may further include a step of adjusting the patient's therapeutic treatment based on the classification obtained.The invention relates to enclosing the use of tranexamic acid (TXA) or a composition comprising it for use in a therapeutic treatment, said use comprising the implementation of a method according to the invention, and means for the implementation of the invention.
Owner:DIAGNOSTICA STAGO SA

Milk protein source urokinase-type plasminogen activator inhibitor peptide and use thereof

The application provides a milk protein source urokinase-type plasminogen activator inhibitory peptide and application thereof. Through a combination of virtual screening by molecular docking and in-vitro experiment verification, two u-PA inhibitory activity polypeptides PEVMGVSK and HIQKEDVPSE derived from bovine milk casein are obtained. The two polypeptides can be stably combined with the u-PA active site through multiple intermolecular forces, have a significant inhibitory effect on u-PA-mediated plasminogen activation, can effectively improve the storage period stability of ultra-high temperature instant sterilized milk, delay protein hydrolysis and aging gel formation, and can inhibit the plasmin clot lysis and MDA-MB-231 human breast cancer cell migration in a concentration-dependent manner. The polypeptides obtained by the application have application potential and practical value in the fields of dairy product quality improvement, hemostatic drugs and anti-cancer drug research, etc. as natural source active ingredients.
Owner:CHINA AGRI UNIV